Cargando…

Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test

It has been over two years since the COVID-19 pandemic began and it is still an unprecedented global challenge. Here, we aim to characterize the antibody profile from a large batch of early COVID-19 cases in China, from January – March 2020. More than 1,000 serum samples from participants in Hubei a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Yiyi, Weng, Youhong, Wu, Yahan, Gao, Fei, Zheng, Xiaojun, Xiong, Xianqin, Lv, Hangjun, Kong, Qingming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204641/
https://www.ncbi.nlm.nih.gov/pubmed/35719335
http://dx.doi.org/10.3389/fcimb.2022.915751
_version_ 1784728971397562368
author Pu, Yiyi
Weng, Youhong
Wu, Yahan
Gao, Fei
Zheng, Xiaojun
Xiong, Xianqin
Lv, Hangjun
Kong, Qingming
author_facet Pu, Yiyi
Weng, Youhong
Wu, Yahan
Gao, Fei
Zheng, Xiaojun
Xiong, Xianqin
Lv, Hangjun
Kong, Qingming
author_sort Pu, Yiyi
collection PubMed
description It has been over two years since the COVID-19 pandemic began and it is still an unprecedented global challenge. Here, we aim to characterize the antibody profile from a large batch of early COVID-19 cases in China, from January – March 2020. More than 1,000 serum samples from participants in Hubei and Zhejiang province were collected. A series of serum samples were also collected along the disease course from 70 patients in Shanghai and Chongqing for longitudinal analysis. The serologic assay (ALLtest) we developed was confirmed to have high sensitivity (92.58% - 97.55%) and high specificity (92.14% - 96.28%) for the detection of SARS-CoV-2 nucleocapsid-specific antibodies. Confirmed cases found in the Hubei Provincial Center for Disease Control and Prevention (HBCDC), showed a significantly (p = 0.0018) higher positive rate from the ALLtest than RNA test. Then, we further identified the disease course, age, sex, and symptoms that were correlating factors with our ALLtest results. In summary, we confirmed the high reliability of our ALLtest and its important role in COVID-19 diagnosis. The correlating factors we identified will require special attention during future clinical application.
format Online
Article
Text
id pubmed-9204641
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92046412022-06-18 Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test Pu, Yiyi Weng, Youhong Wu, Yahan Gao, Fei Zheng, Xiaojun Xiong, Xianqin Lv, Hangjun Kong, Qingming Front Cell Infect Microbiol Cellular and Infection Microbiology It has been over two years since the COVID-19 pandemic began and it is still an unprecedented global challenge. Here, we aim to characterize the antibody profile from a large batch of early COVID-19 cases in China, from January – March 2020. More than 1,000 serum samples from participants in Hubei and Zhejiang province were collected. A series of serum samples were also collected along the disease course from 70 patients in Shanghai and Chongqing for longitudinal analysis. The serologic assay (ALLtest) we developed was confirmed to have high sensitivity (92.58% - 97.55%) and high specificity (92.14% - 96.28%) for the detection of SARS-CoV-2 nucleocapsid-specific antibodies. Confirmed cases found in the Hubei Provincial Center for Disease Control and Prevention (HBCDC), showed a significantly (p = 0.0018) higher positive rate from the ALLtest than RNA test. Then, we further identified the disease course, age, sex, and symptoms that were correlating factors with our ALLtest results. In summary, we confirmed the high reliability of our ALLtest and its important role in COVID-19 diagnosis. The correlating factors we identified will require special attention during future clinical application. Frontiers Media S.A. 2022-05-27 /pmc/articles/PMC9204641/ /pubmed/35719335 http://dx.doi.org/10.3389/fcimb.2022.915751 Text en Copyright © 2022 Pu, Weng, Wu, Gao, Zheng, Xiong, Lv and Kong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Pu, Yiyi
Weng, Youhong
Wu, Yahan
Gao, Fei
Zheng, Xiaojun
Xiong, Xianqin
Lv, Hangjun
Kong, Qingming
Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test
title Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test
title_full Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test
title_fullStr Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test
title_full_unstemmed Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test
title_short Antibody Response to SARS-CoV-2 in the First Batch of COVID-19 Patients in China by a Self-Developed Rapid IgM-IgG Test
title_sort antibody response to sars-cov-2 in the first batch of covid-19 patients in china by a self-developed rapid igm-igg test
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204641/
https://www.ncbi.nlm.nih.gov/pubmed/35719335
http://dx.doi.org/10.3389/fcimb.2022.915751
work_keys_str_mv AT puyiyi antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest
AT wengyouhong antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest
AT wuyahan antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest
AT gaofei antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest
AT zhengxiaojun antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest
AT xiongxianqin antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest
AT lvhangjun antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest
AT kongqingming antibodyresponsetosarscov2inthefirstbatchofcovid19patientsinchinabyaselfdevelopedrapidigmiggtest